Floatz logo

ELCUBRAGISTAT

Transverse Myelitis

Abide TherapeuticsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Transverse Myelitis cohort.

Asset / SponsorPhaseRating
Interferon ?1 (human fibroblast protein moiety)
Beth Israel Deaconess Medical Center
Phase 4BB

Same molecule, other indications

ELCUBRAGISTAT is also rated in:

Longitudinally Extensive Transverse MyelitisDormant
CC
Indicative ·
47 / 100
View asset →
diabetic neuropathyDormant
CC
Indicative ·
47 / 100
View asset →
Small Fiber NeuropathyDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →